Literature DB >> 8018762

Inadequate erythropoietin response to anemia: definition and clinical relevance.

G Barosi.   

Abstract

The development of a specific and sensitive immunoassay for the measurement of serum erythropoietin (s-Epo) allows to improve our understanding of the model of in vivo regulation of erythropoiesis. In most anemias, circulating hemoglobin level determines Epo production which in turn stimulates erythropoietic activity. The disruption of the expected feedback mechanism of Epo production leads to an inadequately low s-Epo. The definition of inadequate Epo response to anemia relies on the documentation of a downregulated dependence of s-Epo on Hb with respect to the same dependence in patients with a physiologically regulated erythropoiesis. Literature reports a wide range of so called adequate s-Epo response to anemia and a number of criteria for judging on the adequateness of s-Epo at a certain degree of anemia. The O/P (observed/predicted) ratio allows categorization of each individual patient. The clinical syndromes in which an inadequate Epo response has been reported are numerous and the mechanisms of defective Epo production are different. A number of evidences clearly point to a relation between responsiveness to r-Hu-Epo and inadequate Epo response. This inequivocabily confirms the role inadequate Epo response plays in the pathogenesis of anemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018762     DOI: 10.1007/bf01737420

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  101 in total

1.  Recombinant human erythropoietin in patients with myelodysplastic syndromes.

Authors:  H C Schouten; E Vellenga; D J van Rhenen; J T de Wolf; P J Coppens; G H Blijham
Journal:  Leukemia       Date:  1991-05       Impact factor: 11.528

2.  Effectiveness of recombinant human erythropoietin therapy in myelodysplastic syndromes.

Authors:  J W Adamson; M Schuster; S Allen; N R Haley
Journal:  Acta Haematol       Date:  1992       Impact factor: 2.195

3.  Relation of serum erythropoietin levels to renal excretory function: evidence for lowered set point for erythropoietin production in chronic renal failure.

Authors:  M Chandra; G K Clemons; M I McVicar
Journal:  J Pediatr       Date:  1988-12       Impact factor: 4.406

4.  Erythropoietin treatment of anemia associated with multiple myeloma.

Authors:  H Ludwig; E Fritz; H Kotzmann; P Höcker; H Gisslinger; U Barnas
Journal:  N Engl J Med       Date:  1990-06-14       Impact factor: 91.245

5.  Changes in serum erythropoietin levels during allogeneic bone marrow transplantation.

Authors:  R J Grace; R G Kendall; C Chapman; A E Hartley; D L Barnard; D R Norfolk
Journal:  Eur J Haematol       Date:  1991-08       Impact factor: 2.997

6.  Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis.

Authors:  G Vreugdenhil; B Manger; C Nieuwenhuizen; R A Feelders; H G van Eijk; A J Swaak
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

7.  Plasma concentration and urinary excretion of erythropoietin in adult nephrotic syndrome.

Authors:  N D Vaziri; C J Kaupke; C H Barton; E Gonzales
Journal:  Am J Med       Date:  1992-01       Impact factor: 4.965

8.  Insulin-like growth factors stimulate erythropoiesis in serum-substituted umbilical cord blood cultures.

Authors:  M Sanders; S Sorba; N Dainiak
Journal:  Exp Hematol       Date:  1993-01       Impact factor: 3.084

9.  Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production.

Authors:  Y Beguin; M Yerna; M Loo; M Weber; G Fillet
Journal:  Br J Haematol       Date:  1992-12       Impact factor: 6.998

10.  Erythrophagocytosis increases the expression of erythroid potentiating activity mRNA in human monocyte-macrophages.

Authors:  G Bergamaschi; H H Recalde; L Ponchio; V Rosti; M Cazzola
Journal:  Exp Hematol       Date:  1993-01       Impact factor: 3.084

View more
  13 in total

1.  Should erythrocyte destruction in vivo be through phagocytosis alone?

Authors:  R K Saxena
Journal:  J Biosci       Date:  2000-03       Impact factor: 1.826

2.  Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin.

Authors:  M Voulgarelis; S I Kokori; J P Ioannidis; A G Tzioufas; D Kyriaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

3.  Anemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute, uncomplicated Plasmodium falciparum malaria.

Authors:  V Nussenblatt; G Mukasa; A Metzger; G Ndeezi; E Garrett; R D Semba
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Nitric oxide donors suppress erythropoietin production in vitro.

Authors:  W Schobersberger; G Hoffmann; J Fandrey
Journal:  Pflugers Arch       Date:  1996-10       Impact factor: 3.657

5.  The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study.

Authors:  Antonio Macciò; Clelia Madeddu; Giulia Gramignano; Carlo Mulas; Luciana Tanca; Maria Cristina Cherchi; Carlo Floris; Itaru Omoto; Antonio Barracca; Tomas Ganz
Journal:  Haematologica       Date:  2014-09-19       Impact factor: 9.941

6.  Serum erythropoietin level in anemic cancer patients.

Authors:  M Ozguroglu; B Arun; G Demir; F Demirelli; N M Mandel; E Buyukunal; S Serdengecti; B Berkarda
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

Review 7.  Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment.

Authors:  S Giannouli; M Voulgarelis; P D Ziakas; A G Tzioufas
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

Review 8.  Stimulating erythropoiesis in inflammatory bowel disease associated anemia.

Authors:  Georgia Tsiolakidou; Ioannis-E Koutroubakis
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 9.  Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition.

Authors:  Angelo Iacobellis; Antonio Ippolito; Angelo Andriulli
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

10.  Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia.

Authors:  K Sogawa; K Numayama-Tsuruta; M Ema; M Abe; H Abe; Y Fujii-Kuriyama
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.